Aquinox slips after Phase II dermatitis miss

Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) lost $0.94 to $15.42 on Tuesday after its AQX-1125 missed the primary endpoint in the Phase II KINSHIP trial to treat atopic dermatitis. The company said the results "do not warrant continued development" for the indication.

In July, Aquinox said the SH2-containing inositol 5'-phosphatase (SHIP) agonist missed the primary endpoint in a Phase II trial to treat chronic obstructive pulmonary disease (see BioCentury Extra, July 9). ...